KLK3 and prostate carcinoma: As PSA levels are not only highly relevant for the psychological wellbeing of prostate cancer patients, but also for decision making regarding ADT or therapy intensification, an intermediate-term gain of PSA levels below baseline seems to be an appropriate endpoint in this setting.